Emergent BioSolutions's Total Assets for the quarter that ended in Dec. 2023 was $1,823 Mil.
During the past 12 months, Emergent BioSolutions's average Total Assets Growth Rate was -32.20% per year.
During the past 3 years, the average Total Assets Growth Rate was -8.90% per year.
During the past 5 years, the average Total Assets Growth Rate was -1.50% per year.
During the past 10 years, the average Total Assets Growth Rate was 18.70% per year.
During the past 13 years, Emergent BioSolutions's highest 3-Year average Total Assets Growth Rate was 52.90%. The lowest was -8.90%. And the median was 20.50%.
Total Assets is connected with ROA %. Emergent BioSolutions's annualizedROA % for the quarter that ended in Dec. 2023 was -10.66%. Total Assets is also linked to Revenue through Asset Turnover. Emergent BioSolutions's Asset Turnover for the quarter that ended in Dec. 2023 was 0.15.
Emergent BioSolutions Total Assets Historical Data
The historical data trend for Emergent BioSolutions's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Emergent BioSolutions Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Total Assets
2,327.30
2,883.20
2,957.70
3,166.30
1,823.20
Emergent BioSolutions Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Total Assets
3,166.30
2,949.80
2,178.80
1,893.10
1,823.20
Emergent BioSolutions Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Emergent BioSolutions's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emergent BioSolutions (NYSE:EBS) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Emergent BioSolutions's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Emergent BioSolutions Total Assets Related Terms
Thank you for viewing the detailed overview of Emergent BioSolutions's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Emergent BioSolutions (Emergent BioSolutions) Business Description
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EBS has been successfully added to your 